Author Correction: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

作者：Lauren A. Byers, Byoung Chul Cho, Alissa J. Cooper, Anne C. Chiang, Ji‐Youn Han, Muhammad Furqan, Afshin Dowlati, Daniel Morgensztern, Kyriakos P. Papadopoulos, Noura J. Choudhury, M. Vieito, Jair Bar, Joo-Hang Kim, Wallace Akerley, Tae Min Kim, Young‐Chul Kim, Luis Paz‐Ares, Myung‐Ju Ahn, Hiroshi Yokouchi, Darius Meiman, Wijith Munasinghe, Oluwadamilola Ogunyankin, Nadine Jahchan, Song Wang, Cristiano Ferlini, Randy Robinson, Frederick J. Kohlhapp, Tammy Palenski, Guillermo Rivell, Pooja Hingorani, Sreenivasa Chandana · 发表于：Nature Medicine · 年份：2026 · DOI：10.1038/s41591-026-04544-x · 研究领域：Lung Cancer Research Studies、HER2/EGFR in Cancer Research、Multiple Myeloma Research and Treatments

In the version of this article initially published, ref. 10 was cited twice and has been replaced by an omitted reference (Faivre E. J. et al. Cancer Re s. https://doi.org/10.1158/1538-7445.AM2024-3148 (2024)), now cited as ref. 11 in the last paragraph of the introduction: “Preclinical studies in patient-derived xenograft models of SEZ6-positive SCLC demonstrated superior activity of ABBV-706 compared to ABBV-011 and standard-of-care chemotherapies 10 . Preliminary results from the ongoing first-in-human phase 1 trial ( NCT05599984 ) to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity and antitumor activity of ABBV-706 in patients with R/R solid tumors (defined as those patients whose disease had progressed on or after treatment with standard of care), including patients with R/R SCLC, demonstrated that ABBV-706 monotherapy had a manageable safety profile and promising antitumor activity, with a confirmed ORR of 43.8% (60.9% in patients with R/R SCLC) 11 .” The reference has been updated in the HTML and PDF version of the article.